NL-OMON29559尚未招募不适用
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.
ReumafondsReade, centrum voor revalidatie en reumatologie0 个研究点目标入组 102 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 102
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. RA according to the ACR 1987 criteria;
- •2. Adalimumab treatment for at least 28 weeks;
排除标准
- •Scheduled surgery in the next 6 months or other pre planned reasons for treatment discontinuation.
研究者
相似试验
已完成
不适用
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritisrheumatoide arthritis10003816NL-OMON41716Reade, centrum voor Revalidatie en Reumatologie55
尚未招募
不适用
Will pazopanib dose individualization result in less variability in pazopanib bloodconcentrations between individuals.Cancer,Solid tumorPhase INL-OMON22313eiden University Medical Center13
已完成
不适用
Therapeutic Drug Monitoring to Individualize the Dosing of pazopanib: a Randomized Pharmacokinetic Feasibility Studyadvanced tumors for which no treatment options are availablerenal cell cancer10038588NL-OMON37356eids Universitair Medisch Centrum13
已完成
3 期
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00011159Friedrich-Schiller-Universität Jena254
进行中（未招募）
1 期
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamEUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208